"We just signed a licensing and manufacturing development deal with an Indian company," he says. "They have about 100 countries on their list that they"re targeting, mostly in southeast Asia, the Middle East, and sub-Saharan Africa. We see primary vaccinations as still being an opportunity in some of the lesser served regions."